Previous close | 14.19 |
Open | 13.94 |
Bid | 13.85 x 3100 |
Ask | 13.86 x 3100 |
Day's range | 13.85 - 13.96 |
52-week range | 13.19 - 17.15 |
Volume | |
Avg. volume | 1,840,970 |
Market cap | 44.356B |
Beta (5Y monthly) | 0.54 |
PE ratio (TTM) | 37.45 |
EPS (TTM) | 0.37 |
Earnings date | N/A |
Forward dividend & yield | 0.64 (4.50%) |
Ex-dividend date | 28 Sept 2023 |
1y target est | 18.36 |
Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE. The initiative, focused on raising awareness of the difficult symptoms of Inflammatory Bowel Disease (IBD), entailed an immersive 24-hour simulation that generated a deeper understanding of how the disease affects the daily lives of patients.
OSAKA, Japan & CAMBRIDGE, Mass., March 26, 2024--Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024.
OSAKA, Japan & CAMBRIDGE, Mass., March 26, 2024--Takeda (TSE: 4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa /cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older.1 ADZYNMA is the first and only approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAM